Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects
datasetposted on 23.04.2021, 07:04 authored by Maria Gallo, Estefanía Moreno, Sira Defaus, Antonio Ortega-Alvaro, Angel Gonzalez, Patricia Robledo, Marco Cavaco, Vera Neves, Miguel A. R. B. Castanho, Vicent Casadó, Leonardo Pardo, Rafael Maldonado, David Andreu
The activation of cannabinoid CB1 receptors (CB1R) by Δ9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CB1R activation, however, also causes cognitive impairment via the serotonin 5HT2A receptor (5HT2AR), a component of a CB1R–5HT2AR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CB1R transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CB1R–5HT2AR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CB1R–5HT2AR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood–brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia.
Read the peer-reviewed publication
orally active 16avoiding side effectsachieve protease resistanceextensive sequence remodelingcannabinoid therapeutic usebased pain managementpeptides reproducing cb2a </ sub1 </ subr – 5htvia </penetrating sequencefight paincannabinoid cbwithout losingthc ),serotonin 5htserious drawbackr transmembraner heteromerr ),preserving analgesialike leadsinduces analgesiainduced analgesiaideal candidatehelices 5cpp sequencescpp ),